⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237675 | 0.63 | — | — | |
| SCHEMBL8031037 | 0.63 | — | — | |
| SCHEMBL33362 | 0.63 | — | — | |
| SCHEMBL1171363 | 0.63 | — | — | |
| Bromide SCHEMBL9067870 | 0.58 | — | — | |
| SCHEMBL12532473 | 0.58 | — | — | |
| SCHEMBL9302189 | 0.58 | — | — | |
| SCHEMBL10342619 | 0.54 | — | — | |
| SCHEMBL18290883 | 0.54 | — | — | |
| SCHEMBL590284 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3079680-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS | Angiogenex, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| WO-2015089495-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS | ANGIOGENEX, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-04 | — | — | US | claimed |
| WO-2012000036-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-05 | — | — | WO | claimed |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | claimed |
| WO-2009051801-A2 | CHEMICAL INHIBITORS OF INHIBITORS OF DIFFERENTIATION | ANGIOGENEX (US) | 2009-04-23 | — | — | WO | claimed |
| US-20210308111-A1 | Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers | WITH GREAT POWER LLC (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3829567-A1 | CLINICAL METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING AMPA RECEPTOR ANTAGONISTS TO TREAT GLIOBLASTOMA AND OTHER CANCERS | With Great Power, LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020023800-A1 | CLINICAL METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING AMPA RECEPTOR ANTAGONISTS TO TREAT GLIOBLASTOMA AND OTHER CANCERS | WITH GREAT POWER, LLC (US) | 2020-01-30 | — | — | WO | disclosed |
| EP-3079680-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS | Angiogenex, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089495-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS | ANGIOGENEX, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20130171158-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-04 | — | — | US | disclosed |
| US-8138356-B2 | Chemical inhibitors of inhibitors of differentiation | Angiogeney, Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2012000036-A1 | TREATMENT OF ABNORMALITIES OF GLUCOSE METABOLISM WITH AN ANTAGONIST OF INHIBITOR OF DIFFERENTIATION 1 | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-05 | — | — | WO | disclosed |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | disclosed |
| WO-2009051801-A2 | CHEMICAL INHIBITORS OF INHIBITORS OF DIFFERENTIATION | ANGIOGENEX (US) | 2009-04-23 | — | — | WO | disclosed |